Rapt Therapeutics (NASDAQ:RAPT) Downgraded to Neutral Rating by HC Wainwright

HC Wainwright downgraded shares of Rapt Therapeutics (NASDAQ:RAPT) from a buy rating to a neutral rating in a research report released on Tuesday, MarketBeat Ratings reports. They currently have $58.00 target price on the stock.

A number of other research analysts have also issued reports on RAPT. Wells Fargo & Company set a $72.00 price objective on Rapt Therapeutics and gave the company an “overweight” rating in a research report on Monday, November 3rd. Guggenheim downgraded shares of Rapt Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday. Barclays lowered their price target on shares of Rapt Therapeutics from $58.00 to $56.00 and set an “overweight” rating for the company in a research report on Friday, November 7th. Leerink Partners upgraded shares of Rapt Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $16.00 to $37.00 in a research report on Friday, September 26th. Finally, TD Cowen started coverage on shares of Rapt Therapeutics in a research report on Thursday, December 18th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Rapt Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $48.22.

Rapt Therapeutics Stock Performance

NASDAQ RAPT opened at $57.57 on Tuesday. Rapt Therapeutics has a one year low of $5.67 and a one year high of $57.61. The company has a 50-day simple moving average of $33.31 and a 200-day simple moving average of $23.72. The firm has a market capitalization of $1.60 billion, a PE ratio of -5.21 and a beta of 0.45.

Rapt Therapeutics (NASDAQ:RAPT) last issued its earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.23. Equities analysts forecast that Rapt Therapeutics will post -2.14 earnings per share for the current year.

Hedge Funds Weigh In On Rapt Therapeutics

Several large investors have recently bought and sold shares of the stock. Invesco Ltd. raised its position in shares of Rapt Therapeutics by 411.7% during the 1st quarter. Invesco Ltd. now owns 58,901 shares of the company’s stock worth $72,000 after buying an additional 47,391 shares in the last quarter. AQR Capital Management LLC bought a new position in shares of Rapt Therapeutics in the first quarter valued at approximately $188,000. Dimensional Fund Advisors LP acquired a new position in shares of Rapt Therapeutics during the third quarter valued at approximately $231,000. Bridgeway Capital Management LLC raised its holdings in Rapt Therapeutics by 32.0% during the third quarter. Bridgeway Capital Management LLC now owns 20,625 shares of the company’s stock worth $532,000 after purchasing an additional 5,000 shares in the last quarter. Finally, UBS Group AG raised its holdings in Rapt Therapeutics by 680.3% during the third quarter. UBS Group AG now owns 28,808 shares of the company’s stock worth $743,000 after purchasing an additional 25,116 shares in the last quarter. Institutional investors and hedge funds own 99.09% of the company’s stock.

Key Headlines Impacting Rapt Therapeutics

Here are the key news stories impacting Rapt Therapeutics this week:

• Positive Sentiment: GSK agreed to acquire Rapt in a definitive deal valuing the company at about $2.2 billion (~$58.00 per share), providing a cash exit at a sizable premium to recent trading and directly causing the stock’s sharp rise. Article Title
• Positive Sentiment: Multiple outlets highlight that GSK gains a late‑stage food allergy antibody (ozureprubart) from Rapt’s pipeline — a strategic fit that supports the acquisition rationale and the deal premium. Article Title
• Positive Sentiment: Rapt’s investors and prior backers benefit: Forbion confirms this is a successful exit from its Growth Fund III, which validates the deal’s value to venture/early investors. Article Title
• Neutral Sentiment: Analysts have mostly left ratings and price targets around the announced deal price (Wells Fargo equal weight with $58 PT; Lifesci/TD Cowen hold), which implies limited near‑term upside beyond the acquisition consideration. Article Title
• Negative Sentiment: Several law firms have announced investigations or shareholder class‑action interest probing whether Rapt’s board negotiated a fair price, which could lead to litigation, procedural delays or settlement costs ahead of closing. Investors should monitor any formal complaints. Article Title
• Neutral Sentiment: Coverage pieces and buy/analysis notes (e.g., Seeking Alpha, The Motley Fool) frame Rapt as an attractive biotech target highlighting its long‑acting IgE candidate; useful context for strategic rationale but secondary to the binding deal terms. Article Title

About Rapt Therapeutics

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.